A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of reintroduction of modified XELOXIRI
combined with molecular targeted drug in patients with metastatic colorectal cancer (mCRC)